Moderna COVID-19 vaccine 94.5% effective in Phase 3 trials, Likely to receive emergency use approval from US FDA

06:20:00 PM, Monday 16th of November 2020 | in coronavirus

Moderna Inc, one of the leading vaccine manufacturers of the United States, announced on Monday that its vaccine candidate was found 94.5% effective in preventing coronavirus. The results were derived from the third and final phase of trials conducted by the biotechnology company. With a nearly 95 percent success rate, Moderna in its press note sounded hopeful of receiving the emergency use authorisation from FDA.